Skip to content

Unraveling the Underlying Mechanisms and Molecular Targets of Ovarian Endometrioma: A Mendelian Randomization Study Based on the Whole Proteome

Unraveling the Underlying Mechanisms and Molecular Targets of Ovarian Endometrioma: A Mendelian Randomization Study Based on the Whole Proteome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113182
Enrollment
Unknown
Registered
2025-11-25
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Case group:NA
Normal control group:None

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Case Group: (1) Females of reproductive age (18-50 years) with regular menstrual cycles in the preceding 3 months; (2) No hormone therapy within the preceding 3 months; (3) No intrauterine device in place; (4) Intraoperative or postoperative pathological diagnosis of endometriosis (EMS), including ovarian endometrioma, peritoneal endometriosis, deep infiltrating endometriosis (DIE), or adenomyosis; (5) Signed informed consent. 2.Normal Control Group: (1) Females of reproductive age (18-50 years) with regular menstrual cycles in the preceding 3 months; (2) No hormone therapy within the preceding 3 months; (3) No clinical or imaging evidence of endometriosis preoperatively; patients presented with other gynecological conditions, and no endometriotic lesions were identified intraoperatively. (4) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. The exclusion criteria for both the case group and control group are identical: (1) Having undergone relevant hormone therapy within the past three months; (2) Concurrent malignant tumours and/or severe internal or surgical conditions; (3) Concurrent significant gynaecological conditions such as endometrial polyps, submucosal uterine fibroids, or pelvic inflammatory disease; (4) Inability to obtain sufficient tissue samples intraoperatively, or autolysis of tissue samples, or missing paraffin blocks; Refusal to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Relative expression fold difference between lesion vs in situ endometrium vs normal endometrium group >=1.5-fold and P < 0.05;The median H-score of lesions was more than 3 points higher than that of controls, with P < 0.05.;PTX3 concentration;

Countries

China

Contacts

Public ContactFei Zeng

The Third Xiangya Hospital of Central South University

zengfeilyx@163.com+86 158 7498 9708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026